Lineagen

Lineagen, Inc. is a privately held personal genomics and biotechnology company based in Salt Lake City, UT. The company was incorporated in 2006 and collaborated with two leading autism research institutions: the University of Utah and The Children's Hospital of Philadelphia (CHOP), to identify novel genetic variants likely causal of autism spectrum disorder.[1][2][3][4] Lineagen was granted an exclusive commercial license to these novel genetic variants. Notably, the markers from CHOP, published in Nature and PLoS Genetics, were named by TIME magazine as one of the top ten medical breakthroughs of 2009.[5][6]

Lineagen, Inc.
TypePrivate
IndustryBiotechnology
FoundedMarch 2006
FoundersMichael S. Paul, Ph.D., Andy Peiffer, M.D., Ph.D.
Headquarters
Salt Lake City, Utah
,
United States
Productspersonal genome testing
ServicesGenetic testing, medical research

Since 2010, Lineagen provides genetic laboratory services to healthcare providers, which include fluorescence in situ hybridization (FISH), karyotyping and chromosomal microarray testing for children with childhood development disorders.[7][8] In 2012, Lineagen and Affymetrix, Inc. announced that the companies have signed an agreement where Lineagen receives exclusive rights to develop a proprietary chromosomal microarray assay based on Affymetrix' GeneChip technology platform.[9][10]

References
  1. Inc., Lineagen. "Lineagen Announces Identification of 39 Genetic Variants as Novel Risk Factors for Developing Autism Spectrum Disorder (ASD)". www.prnewswire.com. Retrieved 2017-02-16.
  2. Tribune, Kirsten Stewart, Heather May And Lindsay Whitehurst The Salt Lake. "University of Utah scientists find 24 new genetic markers for autism". The Salt Lake Tribune. Retrieved 2017-02-16.
  3. Lineagen. "Lineagen Completes 9000-Person Study Focused on Genetic Variants in Individuals Diagnosed with Autism Spectrum Disorder (ASD)". www.prnewswire.com. Retrieved 2017-02-16.
  4. "U of Utah Researchers Improve Genetic Understanding of Autism". healthcare.utah.edu. Retrieved 2017-02-16.
  5. Lineagen. "Lineagen Completes 9000-Person Study Focused on Genetic Variants in Individuals Diagnosed with Autism Spectrum Disorder (ASD)". www.prnewswire.com. Retrieved 2017-02-16.
  6. Philadelphia, The Children's Hospital of (2014-08-10). "CHOP Autism Research Among Time's Top 10 Medical Breakthroughs". www.chop.edu. Retrieved 2017-02-16.
  7. "Lineagen Launches FirstStepDx Genetic Testing and Counseling Service to Help Physicians Diagnose Autism and Developmental Delay Earlier | Business Wire". www.businesswire.com. 2011-01-10. Retrieved 2017-02-16.
  8. "Lineagen, Inc. Closes $5 Million to Complete $10.8 Million Series A Round | Business Wire". www.businesswire.com. 2010-08-30. Retrieved 2017-02-16.
  9. Inc., Lineagen. "Lineagen Applies Affymetrix' GeneChip® Technology to Next-Generation FirstStepDx® Service for Individuals with Developmental Delay and Autism Spectrum Disorders". www.prnewswire.com. Retrieved 2017-02-16.
  10. "LineaGen Research Corporation Selects Affymetrix Santa Clara California Technology to Discover Genes Associated With Autism and Multiple Sclerosis". www.biospace.com. Retrieved 2017-02-16.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.